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B) were included (14 hospitals). There were no signiﬁcant dif-
ferences concerning demographic data, clinical data and severity
of CAP classiﬁed according to PSI-score between the groups.
Total direct costs of CAP amounted to €1528.47 in A and
€1750.01 in B (p < 0.001). Costs for drug acquisition decreased
from €201.00 (A) to €136.55 (B). Costs for nursing and diag-
nostics were almost constant (nursing: A: €554.20, B: €539.25;
diagnostics: A: €79.72, B: €81.17). Hotel costs and costs for non-
medical therapy amounted to €640.03 (A) and €909.36 (B), 
(p < 0.001) and to €53.53 (A) and €83.41 (B), (p < 0.001),
respectively. CONCLUSIONS: Most important cost-driving
factors before and after DRG implementation were hotel and
nursing costs. Drug costs represent only a small part of total
costs and decreased during study period. The signiﬁcant increase
of hotel costs and costs for non-medical therapy may be caused
by higher energy and staff costs. No cost-saving was achieved
from hospital’s perspective after the implementation of DRG.
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OBJECTIVE: To determine the co-morbidity and economical
impact of treatment with tiotropium bromide (TB) for COPD,
in a population cared for by Spanish primary care teams (PCTs)
and specialized physicians, in the context of routine clinical prac-
tice. METHODS: A retrospective observational study including
patients receiving regular treatment with TB, and seen by four
PCTs and two hospital centers during 2004. Principal measures:
age-sex, episodes / co-morbidity, clinical parameters, resources
utilization and pharmacological groups. The costs model was
established differentiating semiﬁxed-indirect costs from the vari-
able costs (pharmacy, tests, referrals) in the PCTs, as well as the
visits, emergencies and hospital admissions registered in the ref-
erence hospital centers. A logistic regression analysis was made
for correlation of the model. The costs were contrasted by analy-
sis of covariance (ANCOVA), with the estimation of marginal
means (Bonferroni adjustment). RESULTS: Of 900 subjects with
COPD, 14.3% (n = 129) received treatment with TB (CI:
12.0–16.6%). The mean episodes/patient/year was 2.1 ± 1.4 vs.
1.8 ± 1.3 (p = NS), seriousness/severity 41.3% vs. 26.3% (p =
0.001), deﬁned daily dose (DDD) 5928.5 ± 9624.1 vs. 6187.7 ±
12471.3 (p = NS) and number visits/patient/year 15.1 ± 9.4 vs.
17.3 ± 11.9 (p = 0.044). After adjustment by age and sex, TB
use was associated with diabetes mellitus (OR = 1.6; CI =
1.0–2.5; p = 0.034) and patient severity (OR = 1.8; CI = 1.2–2.8;
p = 0.004). Quantiﬁcation of unit cost/year was €2793.22 ±
€3166.30 (€3354.17 ± €3423.25 vs. €2699.36 ± €3113.75; p =
0.001). The adjusted patient cost/year was €2831.22 (SE =
217.32) with TB versus €2786.86 € (SE = 88.53) without TB, 
p = NS. CONCLUSIONS: TB is associated as therapy comple-
menting habitual treatment, with the presence of diabetes, and
with the severity of the disease. The costs of COPD entail impor-
tant resource utilization. The prescription of TB does not imply
a greater global cost of the disease and could give rise to fewer
outpatient follow-up visits. Further studies are needed to conﬁrm
the consistency of the results obtained.
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OBJECTIVE: To compare the risk of hospitalizations and/or
emergency department (ED) visits among Medicaid COPD
patients prescribed various medications. This study analyzed
both COPD-related events and all-cause events. METHODS:
Observational, retrospective study in Texas Medicaid. Eligible
patients were aged 40 to 65 years, with a primary or secondary
diagnosis of COPD, and with > = 1 prescription for ipratropium
(IPR), inhaled corticosteroids (ICS), salmeterol (SAL) or ﬂutica-
sone proprionate/ salmeterol (FSC) between September 1, 2000,
and December 31, 2003. Outcome of interest was time to ﬁrst
ED/hospitalizations 12 months post index medication date. A
matched propensity sample was used as a sensitivity analysis.
RESULTS: A total of 9671 patients were included: IPR (5786),
ICS (1561), SAL (600), and FSC (1724). After adjusting for base-
line characteristics (prior ED/hospitalizations, oral corticos-
teroid, albuterol, theophylline use, comorbidities, asthma
diagnosis, age, race, and gender), compared with IPR, all cohorts
were associated with signiﬁcantly lower risk of a COPD-related
ED/hosp event; ICS (HR 0.822 95% CI, 0.694–0.974), SAL
(HR, 0.721 95% CI, 0.551–0.944), FSC (HR, 0.720 95% CI,
0.605–0.857). When comparing all-cause events, only FSC had
a signiﬁcantly lower risk than IPR (FSC, [HR 0.894 95% CI,
0.842–0.949]). Propensity matched sample of FSC versus IPR (1
: 1), showed that FSC had a lower risk for both COPD-related
(HR, 0.760 [95% CI, 0.617–0.936]) and all-cause (HR, 0.909
[95% CI, 0.845–0.978]) ED/hosp events. CONCLUSIONS: FSC
was associated with a signiﬁcantly lower risk of COPD-related
and all-cause ED/hosp events compared with IPR during 12
months of therapy in a Medicaid population. Additional studies
are needed to conﬁrm these ﬁnding across different populations.
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OBJECTIVES: To quantify the economic consequences of the
lack of adherence to GOLD guidelines regarding treatment of
COPD in Spain. METHODS: A literature review was used to
identify observational studies describing drugs used in patients
with COPD and different levels of severity in Spain (FEV1 80%-
50% of predicted–mild- and FEV1 <50%–moderate/severe-). A
pooled analysis of these studies was combined with drug costs
(using different assumptions) to obtain the “observed cost” of
COPD treatment. An “expected cost” was obtained by using the
minimum and maximum treatment derived from GOLD recom-
mendations, so obtaining a range of the expected cost of med-
ications for COPD for different levels of severity. An economic
model was built up to compare different scenarios of “observed
vs expected” costs of COPD treatment and a Monte-Carlo sim-
ulation was carried out to estimate the proportion of patients in
the real word setting presenting higher or lower costs than the
range of ideal costs derived from GOLD recommendations.
RESULTS: Average medication cost of COPD patients in Spain
